AndhraNews.net
Home » Business News » 2013 » July » July 2, 2013

Galapagos initiates Phase 1 trial as part of its alliance with Janssen Pharmaceutica NV


July 2, 2013 - Mechelen, Belgium



* GLPG1205 is a first-in-class molecule to enter the clinic
* Candidate drug targets inflammation of the bowel
* Galapagos receives EUR6.6 million milestone payment

Galapagos NV (Euronext: GLPG) announced today that it has initiated aFirst-in-Human (FIH) Phase 1 study with GLPG1205 as part of its alliancewith Janssen Pharmaceutica NV. This achievement triggered a milestonepayment of EUR6.6 million to Galapagos, which will contribute to H12013 revenues.

In 2007, Galapagos announced an alliance agreement with JanssenPharmaceutica NVproviding the option to worldwide, commercial licenses to certainGalapagosinternal inflammatory disease programs. These programs include a noveltargetfor inflammatory disorders that was identified and validated by Galapagosusingits proprietary target discovery engine. Subsequent Galapagos researchled tothe discovery of GLPG1205, a first-in-class molecule that enters theclinic forinflammatory disorders. Galapagos will be responsible for execution ofPhase 1and Phase 2A studies with GLPG1205.

"With GLPG1205, Galapagos has moved another proprietary molecule with anovelmode-of-action into the clinic. This program has the potential to unlocka newclass of drugs to treat inflammatory disorders. Consistent with ourstrategy ofbringing innovative molecules to the clinic, this is the fourth First-in-Humanstudy with a novel mode-of-action," said Onno van de Stolpe, CEO ofGalapagos."The alliance with Janssen is the second where Galapagos has broughtprogramsfrom target to the clinic. Today's achievement brings Galapagos'pipeline tofive clinical programs, and we are pleased we will be driving the Phase1 and2A studies forward with this potential new therapy in inflammatorydisease."

The aim of this FIH study is to evaluate the safety,tolerability,pharmacokinetics, and pharmacodynamics of oral single and multipleascendingdoses of GLPG1205. The randomized, double-blind, placebo-controlled,singlecenter study will be conducted in 40 healthy volunteers in Belgium.In thefirst part of the study, single ascending doses will be evaluated.In thesecond part, the new compound will be administered daily for 14 days.Galapagosexpects to disclose topline results from the study by the end of this year.

About Galapagos

Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,with a large pipeline of five clinical, six pre-clinical, and 30discoverysmall-molecule and antibody programs in cystic fibrosis,inflammation,antibiotics, metabolic disease, and other indications.GLPG0634 is an orally-available, selective inhibitor of JAK1 for thetreatmentof rheumatoid arthritis and potentially other inflammatory diseases,currentlyin Phase 2B studies in RA and about to enter Phase 2 studies inCrohn'sdisease. AbbVie and Galapagos signed a worldwide license agreementwherebyAbbVie will be responsible for further development and commercializationafterPhase 2B. Galapagos has another selective JAK1 inhibitor in Phase 2 inlupusand psoriasis, GSK2586184 (formerly GLPG0778, in-licensed byGlaxoSmithKline in2012). GLPG0187 is a novel integrin receptor antagonist currently in aPhase1B patient study in metastasis. GLPG0974 is the first inhibitor of FFA2to beevaluated clinically for the treatment of IBD; this program is currentlyin aProof of Concept Phase 2 study. GLPG1205 is a first-in-class moleculethattargets inflammatory disorders and is currently in a First-in-HumanPhase 1study.

The Galapagos Group, including fee-for-service companies BioFocus,Argenta andFidelta, has 800 employees and operates facilities in five countries,withglobal headquarters in Mechelen, Belgium. Further information at:www.glpg.com

Galapagos forward-looking statements

This release may contain forward-looking statements, including, withoutlimitation, statements containing the words "believes," "anticipates,""expects," "intends," "plans," "seeks," "estimates," "may," "will,""could,""stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties andotherfactors which might cause the actual results, financial condition,performanceor achievements of Galapagos, or industry results, to be materiallydifferentfrom any historic or future results, financial conditions, performance orachievements expressed or implied by such forward-looking statements. Giventhese uncertainties, the reader is advised not to place any undue relianceonsuch forward-looking statements. These forward-looking statements speakonly asof the date of publication of this document. Galapagos expressly disclaimsanyobligation to update any such forward-looking statements in this documenttoreflect any change in its expectations with regard thereto or any change inevents, conditions or circumstances on which any such statement is based,unlessrequired by law or regulation.

Galapagos initiates Phase 1 trial:http://hugin.info/133350/R/1713439/568789.pdf

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Galapagos NV via Thomson Reuters ONE

[HUG#1713439]

CONTACT

Galapagos NV
Piet Wigerinck
Chief Scientific Officer

Tel: +32 477 62 7103

Elizabeth Goodwin
Director Investor Relations
Tel: +31 6 2291 6240
Email Contact

MarketWire

Comment on this story

Share